drugset / Trial / NCT02800889
Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1, open-label, dose escalation study to evaluate the safety, pharmacokinetics, and antitumor activity of pixantrone in pediatric patients with relapsed or refractory solid tumors (excluding those with CNS tumors) or lymphoma.
Timeline
- Start
- 2016-10-24
- Primary completion
- 2018-07-10
- Completion
- 2018-07-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pixantrone | Small molecule | 40 mg/m2 | Intravenous |
| Subject | Pixantrone | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Pixantrone | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Pixantrone | Small molecule | 70 mg/m2 | Intravenous |